Abstract: A rail vehicle has at least one bogie and an electrical supply device with a fuse protection apparatus, a distributing apparatus, which is arranged in the rail vehicle interior and which is electrically connected to the fuse protection apparatus. A first housing is arranged in the rail vehicle under floor area and includes electrical components that are electrically connected to the distributing apparatus. The bogie, viewed in the direction of travel of the rail vehicle, is arranged between the distributing apparatus and the first housing. In order to provide a generic rail vehicle for which short cable paths are achieved and doubling of cables is avoided in a bogie area, the fuse protection apparatus is arranged in a second housing different from the first housing. The first and second housings, relative to the direction, are arranged on both sides of the bogie.

Abstract: A rail vehicle has at least one bogie and an electrical supply device with a fuse protection apparatus, a distributing apparatus, which is arranged in the rail vehicle interior and which is electrically connected to the fuse protection apparatus. A first housing is arranged in the rail vehicle under floor area and includes electrical components that are electrically connected to the distributing apparatus. The bogie, viewed in the direction of travel of the rail vehicle, is arranged between the distributing apparatus and the first housing. In order to provide a generic rail vehicle for which short cable paths are achieved and doubling of cables is avoided in a bogie area, the fuse protection apparatus is arranged in a second housing different from the first housing. The first and second housings, relative to the direction, are arranged on both sides of the bogie.

Abstract: A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a KLH1 haemocyanin, a haemocyanin domain or a fragment thereof with the immunological properties of at least one domain of haemocyanin, and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct can also comprise a nucleic acid sequence that codes for an antigen. Host cells are also contemplated that contain the nucleic acid molecule or construct and a recombinant expression product thereof. The invention further relates to a pharmaceutical composition that comprises the expression product and antibodies obtainable by immunization of an animal therewith, as well as the use of antibodies in screening methods for the identification of tumors.

Abstract: A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a HLH2 haemocyanin polypeptide and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct further can comprise a nucleic acid sequence that codes for an antigen. Host cells are also contemplated that contain the nucleic acid molecules or construct and recombinant expression product thereof. The invention further relates to a pharmaceutical composition that comprises the expression product of that nucleic acid and antibodies obtainable by immunization of an animal therewith, as well as use of the antibodies in screening methods for the identification of tumors.

Abstract: A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a haemocyanin, a haemocyanin domain or a fragment thereof with the immunological properties of at least one domain of haemocyanin, and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct furthermore can comprise a nucleic acid sequence that codes for an antigen. Host cells are also contemplated that contain the nucleic acid molecule or construct and a recombinant expression product thereof. The invention furthermore relates to a pharmaceutical composition that comprises the expression product and antibodies obtainable by immunization of an animal therewith, as well as the use the antibodies in screening methods for the identification of tumors.

Abstract: A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a haemocyanin, a haemocyanin domain or a fragment thereof with the immunological properties of at least one domain of haemocyanin, and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct furthermore can comprise a nucleic acid sequence that codes for an antigen. Host cells are also contemplated that contain the nucleic acid molecule or construct and a recombinant expression product thereof. The invention furthermore relates to a pharmaceutical composition that comprises the expression product and antibodies obtainable by immunization of an animal therewith, as well as the use the antibodies in screening methods for the identification of tumors.